A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.

Anjali Rohatgi,Ryan Campbell Massa,William E. Gooding,Tullia C. Bruno,Dario A. A. Vignali,John M. Kirkwood

A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.

2020

Anjali Rohatgi
Ryan Campbell Massa
William E. Gooding
Tullia C. Bruno
Dario A. A. Vignali
John M. Kirkwood

TPS10085Background: Novel checkpoint inhibitors are a promising treatment for advanced melanoma, as only a fraction of patients have durable responses to current FDA-approved immunotherapy. Lymphoc...

Keywords:

Prior Immunotherapy
Monoclonal antibody
Pathology
Nivolumab
LAG3
Phases of clinical research
metastatic melanoma
in patient
Medicine
Cancer research
Anti-PD1 Monoclonal Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations